Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535657 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL4419612 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL11606150 | 0.81 | CYP3A4 (0.44) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL29528605 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL251913 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL251914 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL253024 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL253023 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL28449368 | 0.81 | GABRA1 (0.39) | GABRA1GABRB2CYP3A4SLC6A2HTR2C | |
| SCHEMBL29528763 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3063281-A2 | PROCESS FOR THE CHIRAL RESOLUTION OF ACETATES TO (R)-ALCOHOLS EMPLOYING FUSARIUM PROLIFERATUM | Council of Scientific and Industrial Research (IN) | 2016-09-07 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015063796-A2 | A PROCESS OF CHIRAL RESOLUTION OF CYCLIC AND ACYCLIC ACETATES TO ENANTIOMERICALLY PURE (R)--ALCOHOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-05-07 | — | — | WO | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1809586-A1 | PROCESS FOR THE DE-ENRICHMENT OF ENANTIOMERICALLY ENRICHED SUBSTRATES | Avecia Pharmaceuticals Limited (GB) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006096132-A1 | IMMOBILISED ENZYMES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006068879-A1 | TETRADENTATE LIGANDS AND METAL COMPLEXES THEREOF FOR ASYMMETRIC CATALYSIS | EASTMAN CHEMICAL COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006046062-A1 | PROCESS FOR THE DE-ENRICHMENT OF ENANTIOMERICALLY ENRICHED SUBSTRATES | AVECIA PHARMACEUTICALS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| EP-1556427-A2 | MACROPOROUS MATERIAL IN THE FORM OF PLASTIC PEARLS | Röhm GmbH & Co. KG (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039854-A2 | MACROPOROUS MATERIAL IN THE FORM OF PLASTIC PEARLS | RÖHM GMBH & CO.KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-1222163-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025189-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | GABRA1 4355/4885GABRB2 3892/4885CYP3A4 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.